prostaglandin analogue

Intracameral prostaglandin analogue therapy delivers durable benefitFive patients receiving an extended-release travoprost delivery system (ENV515, Envisia Therapeutics) in the anterior chamber have ongoing IOP-lowering with follow-up to 9 months in an ongoing study.
Better alternatives to standalone prostaglandin analog therapyPhysicians have the option of various adjunctive therapy when prostaglandin analog therapy alone is not sufficiently potent to lower IOP, i.e., they can add one agent, a fixed-combination therapy, or perform selective laser trabeculoplasty (SLT).
2015's glaucoma therapy advancesWhile no new drug shook up the world of glaucoma in 2015, a variety of promising agents made incremental advances toward the market with their true potential as yet unproven. Manufacturers have continued to refine approaches to existing drugs.
Glaucoma therapy: What if a PGA isn’t enough?In this article, Dr Tanna discusses treatment options for glaucoma patients who do not show satisfactory response to a PGA while taking into consideration the two key therapeutic choice factors: IOP-lowering efficacy and tolerability.
Low copay of generic PGA may improve adherenceIn patients taking PGAs for glaucoma, adherence to therapy may increase with the prescription of generic latanoprost, which has a lower copay than brand-name PGAs, according to a new study published online.
New glaucoma drugs aim to shake up marketReuters recently reported on a new wave of drugs in development that it says will shake up glaucoma treatments. When the consumer media is giving your patients direct information about eye care, are you ready to answer their questions?
Rethinking prostaglandin analogs side effectsI recently came across a journal publication describing a patient with Crohn’s disease and open-angle glaucoma.1 Essentially, the patient’s treatment with topical latanoprost was associated with an exacerbation of her Crohn’s disease.
Fixed dose of ROCK/NET inhibitor, latanoprost meets endpointA fixed-dose combination containing an investigational rho kinase/norepinephrine transporter inhibitor and latanoprost 0.005% achieved its primary endpoint, showing potential as a high-efficacy, IOP-lowering therapy in a phase IIb trial.